Johnson & Johnson (NYSE:JNJ – Get Free Report) insider William Hait sold 14,698 shares of the company’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Johnson & Johnson Trading Up 0.6 %
NYSE:JNJ opened at $173.71 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The company has a market cap of $451.43 billion, a PE ratio of 35.16, a P/E/G ratio of 2.90 and a beta of 0.55. The business’s 50 day moving average is $161.14 and its two-hundred day moving average is $161.22. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 37.01% and a net margin of 13.35%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 EPS. On average, analysts predict that Johnson & Johnson will post 10.76 EPS for the current year.
Johnson & Johnson Announces Dividend
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the business. Folger Nolan Fleming Douglas Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 1.4% during the second quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 108,816 shares of the company’s stock valued at $18,011,000 after buying an additional 1,458 shares in the last quarter. Selway Asset Management grew its stake in Johnson & Johnson by 0.7% in the second quarter. Selway Asset Management now owns 13,891 shares of the company’s stock valued at $2,299,000 after purchasing an additional 95 shares in the last quarter. Barrett & Company Inc. grew its stake in Johnson & Johnson by 5.5% in the second quarter. Barrett & Company Inc. now owns 9,766 shares of the company’s stock valued at $1,617,000 after purchasing an additional 508 shares in the last quarter. LMG Wealth Partners LLC grew its stake in Johnson & Johnson by 0.9% in the second quarter. LMG Wealth Partners LLC now owns 14,617 shares of the company’s stock valued at $2,419,000 after purchasing an additional 137 shares in the last quarter. Finally, ETF Store Inc. grew its stake in Johnson & Johnson by 4.8% in the second quarter. ETF Store Inc. now owns 1,712 shares of the company’s stock valued at $272,000 after purchasing an additional 79 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the subject of several research analyst reports. Barclays upped their price target on Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Monday. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Stifel Nicolaus upped their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Atlantic Securities decreased their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $171.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- How to Invest in Energy
- Is AI On The Verge Of A Monster Short Squeeze Breakout?
- Retail Stocks Investing, Explained
- Chipotle Mexican Grill Serves Up Another Entry PointÂ
- Canada Bond Market Holiday: How to Invest and Trade
- 7 Best Hotel REITs to Buy Now
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
